Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EONS 12: Opening session

4921 - EONS - Genetics, biomarkers and symptoms during breast cancer: A scoping review of literature


28 Sep 2019


EONS 12: Opening session


Seyma Pasalak


Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276


S.I. Pasalak, M. Seven, G. Bagcivan

Author affiliations

  • School Of Nursing, Koç University, 34010 - Istanbul/TR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4921


Current evidence suggests that sensitive and specific biomarkers will be available to be used for the assessment and management of symptoms. The aims of the study; to explore the existing research evidence pertaining to biomarkers’/genes’ investigation within breast cancer symptom science, and to identify biomarkers to be targeted in future symptom research intervention among breast cancer patients.


Search terms for this systematic review, included “biomarker*, biological marker*, genetics, genomics, genes, genotype, phenotype, AND oncology, cancer, neoplasm, AND sign*, symptom*, quality of life, cognitive functions/performance or cognitive impairment, sleep disturbances, impaired sleep/insomnia, fatique, pain, GI distress, nausea, vomiting, appetite changes, weight loss, neuropathy, xerostomia and mouth ulcers, neuropathy, skin and nail changes, dyspnea, depression, anxiety”. A comprehensive multistep search of CINAHL (160), Cochrane (41), OVID (18), PsycInfo (59), Pubmed (773), Web of Science (527) for identified articles to include in February 2019. Total 1573 articles found and after discarding the duplicates, 1301 articles were checked by title then abstract. A sample of 114 primary research articles were remained for full text review. Total 55 articles met the inclusion criteria in the review.


Twenty-three articles in different cancer types including breast cancer and 32 articles including only breast cancer patients were reviewed in details. The reference lists of these articles will be checked to find additional studies for scoping reviews. These studies were summarized using the following pre-specified evaluation criteria: the aim of study, major findings; genes and associated polymorphisms investigated, sample characteristics (i.e., size, setting, age); symptom’s assessment (i.e., timing). Symptoms investigated are sleep disturbances, anxiety, cognitive function (attentional function, memory complaints), peripheral neuropathy- neurotoxicity, depressive symptoms, fatigue- energy level, nausea-vomiting, pain (cancer pain, breast pain), quality of life, secondary lymphedema.


In future, candidate genes may be targeted to describe mechanisms of symptoms or symptoms clusters for potential precision treatments and effective symptom management strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.